MX346555B - Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1). - Google Patents

Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).

Info

Publication number
MX346555B
MX346555B MX2015009802A MX2015009802A MX346555B MX 346555 B MX346555 B MX 346555B MX 2015009802 A MX2015009802 A MX 2015009802A MX 2015009802 A MX2015009802 A MX 2015009802A MX 346555 B MX346555 B MX 346555B
Authority
MX
Mexico
Prior art keywords
methods
cancer therapy
increasing efficacy
folr1
folr1 cancer
Prior art date
Application number
MX2015009802A
Other languages
English (en)
Spanish (es)
Inventor
N Carrigan Christina
R Whiteman Kathleen
Payne Gillian
Ladd Sharron
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MX346555B publication Critical patent/MX346555B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
MX2015009802A 2011-04-01 2012-03-30 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1). MX346555B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471007P 2011-04-01 2011-04-01
PCT/US2012/031544 WO2012135675A2 (en) 2011-04-01 2012-03-30 Methods for increasing efficacy of folr1 cancer therapy

Publications (1)

Publication Number Publication Date
MX346555B true MX346555B (es) 2017-03-24

Family

ID=46932392

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015009802A MX346555B (es) 2011-04-01 2012-03-30 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
MX2013011098A MX340640B (es) 2011-04-01 2012-03-30 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
MX2019010336A MX2019010336A (es) 2011-04-01 2013-09-26 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2013011098A MX340640B (es) 2011-04-01 2012-03-30 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
MX2019010336A MX2019010336A (es) 2011-04-01 2013-09-26 Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).

Country Status (30)

Country Link
US (5) US8709432B2 (cg-RX-API-DMAC7.html)
EP (4) EP3636279B1 (cg-RX-API-DMAC7.html)
JP (7) JP6018621B2 (cg-RX-API-DMAC7.html)
KR (6) KR102489185B1 (cg-RX-API-DMAC7.html)
CN (3) CN108743965A (cg-RX-API-DMAC7.html)
AU (4) AU2012236219B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013025415B1 (cg-RX-API-DMAC7.html)
CA (2) CA2831426C (cg-RX-API-DMAC7.html)
CY (1) CY1119960T1 (cg-RX-API-DMAC7.html)
DK (1) DK2694106T3 (cg-RX-API-DMAC7.html)
EA (2) EA201791843A3 (cg-RX-API-DMAC7.html)
ES (2) ES2661466T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180358T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036172T2 (cg-RX-API-DMAC7.html)
IL (5) IL281714B2 (cg-RX-API-DMAC7.html)
LT (1) LT2694106T (cg-RX-API-DMAC7.html)
ME (1) ME03025B (cg-RX-API-DMAC7.html)
MX (3) MX346555B (cg-RX-API-DMAC7.html)
MY (2) MY180894A (cg-RX-API-DMAC7.html)
NO (1) NO2893540T3 (cg-RX-API-DMAC7.html)
PL (1) PL2694106T3 (cg-RX-API-DMAC7.html)
PT (1) PT2694106T (cg-RX-API-DMAC7.html)
RS (1) RS56916B1 (cg-RX-API-DMAC7.html)
SG (2) SG193514A1 (cg-RX-API-DMAC7.html)
SI (1) SI2694106T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800103T1 (cg-RX-API-DMAC7.html)
TR (1) TR201802659T4 (cg-RX-API-DMAC7.html)
UA (2) UA125636C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012135675A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202007440B (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
WO2007024536A2 (en) 2005-08-24 2007-03-01 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
SG176068A1 (en) 2009-06-03 2011-12-29 Immunogen Inc Conjugation methods
RS55738B1 (sr) 2010-02-24 2017-07-31 Immunogen Inc Imunokonjugati protiv folatnog receptora 1 i njihove upotrebe
CN103717262B (zh) 2011-03-29 2017-09-15 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
BR112013025415B1 (pt) 2011-04-01 2021-03-16 Immunogen, Inc uso de um imunoconjugado antirreceptor de folato 1 (folr1)
MX362514B (es) 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
MX359599B (es) 2012-10-04 2018-09-12 Immunogen Inc Uso de una membrana de pvdf para purificar conjugados de agentes de unión celular y agentes citotóxicos.
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
KR20150094617A (ko) 2012-12-07 2015-08-19 교와 핫꼬 기린 가부시키가이샤 항 ｆｏｌｒ１ 항체
RU2015129800A (ru) 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
RU2015149285A (ru) * 2013-05-14 2017-06-19 Иммьюноджен Инк. Схемы дозирования иммуноконъюгата anti-folr1
PL3038650T3 (pl) 2013-08-30 2021-11-22 Immunogen, Inc. Przeciwciała i testy do wykrywania receptora folianu 1
IL298044B2 (en) 2013-10-08 2024-11-01 Immunogen Inc Dosing regimens of anti-FOLR1 immunoconjugate
US20150297744A1 (en) * 2014-03-28 2015-10-22 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
US9950077B2 (en) * 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
CA2958882A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
SG11201701455SA (en) 2014-09-03 2017-03-30 Immunogen Inc Cytotoxic benzodiazepine derivatives
WO2016079076A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules agiant folr1 and cd3
LT3221355T (lt) 2014-11-20 2020-12-28 F. Hoffmann-La Roche Ag Kombinuotoji t ląsteles aktyvinančių bispecifinių antigeną surišančių molekulių cd3 bei folato receptoriaus 1 (folr1) ir pd-1 ašą surišančių antagonistų terapija
PT3221357T (pt) 2014-11-20 2020-07-28 Hoffmann La Roche Cadeias leves comuns e métodos de utilização
AU2016298439B2 (en) * 2015-07-30 2018-11-08 Expression Pathology, Inc. Quantifying FR-alpha and GART proteins for optimal cancer therapy
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
PT3380525T (pt) 2015-11-25 2024-02-05 Immunogen Inc Formulações farmacêuticas e métodos que as utilizam
MX395252B (es) 2016-01-08 2025-03-25 Altrubio Inc Anticuerpos tetravalentes anti ligando-1 de glicoproteina p-selectina (psgl-1) y usos de estos.
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
EP3518943A4 (en) 2016-09-28 2020-04-22 Atossa Therapeutics, Inc. METHOD FOR ADAPTIVE CELL THERAPY
KR102681168B1 (ko) 2017-02-28 2024-07-04 이뮤노젠 아이엔씨 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
IT201700087291A1 (it) * 2017-07-28 2019-01-28 Fondazione St Italiano Tecnologia Metodo di imaging di un campione biologico e relativa sonda
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019133652A1 (en) 2017-12-28 2019-07-04 Immunogen, Inc. Benzodiazepine derivatives
US11873335B2 (en) * 2018-03-13 2024-01-16 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
TW202102270A (zh) 2019-03-21 2021-01-16 美商伊繆諾金公司 製備細胞結合劑-藥物結合物之方法
TW202102506A (zh) 2019-03-29 2021-01-16 美商伊繆諾金公司 苯二氮平衍生物
EP4316524A3 (en) 2019-04-26 2024-04-24 ImmunoGen, Inc. Camptothecin derivatives
CN114222756A (zh) 2019-04-29 2022-03-22 伊缪诺金公司 双互补位FR-α抗体和免疫缀合物
WO2020247827A1 (en) * 2019-06-06 2020-12-10 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
CN111579798A (zh) * 2020-05-29 2020-08-25 深圳市锦欣医疗科技创新中心有限公司 一种评估子宫内膜容受性的试剂盒及其使用方法
CA3220817A1 (en) * 2021-06-04 2022-12-08 Eric WESTIN Treatment of cancer in patients with soluble fr-alpha
CA3249553A1 (en) * 2022-03-11 2023-09-14 Astrazeneca Ab METHOD FOR RATING ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
US12258396B1 (en) * 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
CN117741149A (zh) * 2024-02-19 2024-03-22 卡秋(江苏)生物科技有限公司 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用
WO2025195447A1 (zh) * 2024-03-22 2025-09-25 北京桦冠生物技术有限公司 结合folr1蛋白的抗体、抗体药物偶联物及其用途

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US20030148406A1 (en) 1992-03-17 2003-08-07 David John King Multivalent antigen-binding proteins
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
WO2000023082A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
IT1307309B1 (it) 1999-12-30 2001-10-30 Enea Ente Nuove Tec Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
PL211872B1 (pl) 2000-03-31 2012-07-31 Purdue Research Foundation Kompozycja farmaceutyczna
DE10037759A1 (de) 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
MXPA03007316A (es) 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
MXPA03010035A (es) 2001-05-02 2004-06-30 Purdue Research Foundation Tratamiento y diagnostico de enfermedades mediadas por macrofagos.
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
AU2003211337A1 (en) 2002-03-01 2003-09-16 Japan Envirochemicals, Ltd. Proteins capable of binding to female sex hormones and process for producing the same
CA2482607C (en) 2002-04-22 2013-06-11 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
EP1481993A1 (en) 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP1626993B1 (en) 2003-05-09 2015-03-11 Duke University Cd20-specific antibodies and methods of employing same
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MX369959B (es) 2003-05-14 2019-11-27 Immunogen Inc Composicion de farmaco conjugado.
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US20050170368A1 (en) 2003-07-02 2005-08-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2548942C (en) 2003-12-05 2013-10-15 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Anti-sars monoclonal antibodies
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
ES2427177T3 (es) 2004-04-27 2013-10-29 Galapagos N.V. Métodos, agentes y ensayos de detección de compuestos para inducir diferenciación de células de mamífero no diferenciadas para dar lugar a osteoblastos
US7241598B2 (en) 2004-06-29 2007-07-10 The Chinese University Of Hong Kong Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
EP1812062B1 (en) 2004-10-25 2022-03-09 Merck Sharp & Dohme Corp. Anti-addl antibodies and uses thereof
CA2595171C (en) 2004-12-21 2015-03-17 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
MX2007008017A (es) 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
US7700738B2 (en) 2005-01-27 2010-04-20 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
DE602006012816D1 (de) * 2005-03-30 2010-04-22 Endocyte Inc Tifizierung von zellulären folat vitamin rezeptoren
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
EP1888639A1 (en) 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
WO2006122822A2 (en) 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
CN101273063A (zh) 2005-05-24 2008-09-24 阿维斯塔金格兰技术有限公司 用于b细胞淋巴瘤治疗的针对cd20的单克隆抗体的生产方法
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
WO2007022416A2 (en) 2005-08-18 2007-02-22 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
EP1938104A2 (en) 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
AU2006328470B2 (en) 2005-12-20 2012-08-16 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
US8486412B2 (en) 2006-06-01 2013-07-16 Mayo Foundation For Medical Education And Research Immunity to folate receptors
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
EP1900533A1 (de) 2006-09-16 2008-03-19 J. Zimmer Maschinenbau Gesellschaft m.b.H. Vorrichtung zum Auftragen von Substanz auf flächige Substrate
UA106194C2 (ru) 2006-10-12 2014-08-11 Чугей Сейяку Кабусики Кайся Диагностика и лечение рака с применением антитела к ereg
JP5632582B2 (ja) 2006-12-14 2014-11-26 中外製薬株式会社 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
CA2673725C (en) 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
EP2604283A1 (en) 2007-02-16 2013-06-19 KTB Tumorforschungsgesellschaft mbH Receptor And Antigen Targeted Prodrug
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
WO2008145136A1 (en) 2007-05-30 2008-12-04 Aarhus Universitet Stat3 inactivation by inhibition of the folate receptor pathway
CA2690943A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
AU2008282863A1 (en) 2007-07-31 2009-02-05 Merck Sharp & Dohme Corp. IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
CN101139613B (zh) 2007-08-01 2011-06-08 姜荣锡 抗肿瘤二元多肽及其应用与制备方法
WO2009032974A2 (en) 2007-09-06 2009-03-12 Tripath Imaging, Inc. Nucleic acid-based methods for the detection of ovarian cancer
AU2008340017B2 (en) 2007-12-21 2012-04-05 Novartis Ag Organic compounds
EP3064512B1 (en) 2008-01-11 2023-08-30 The University of Tokyo Anti-cldn6 antibody
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
KR20230003298A (ko) 2008-04-30 2023-01-05 이뮤노젠 아이엔씨 가교제 및 그 용도
US8383351B2 (en) 2008-06-11 2013-02-26 Oxford Brookes University Antibody to inhibin/ activin β-B subunit
PL2349274T3 (pl) 2008-09-17 2025-09-22 Endocyte, Inc. Koniugaty antyfolianów wiążące się z receptorem folianów
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US8420329B2 (en) 2008-11-20 2013-04-16 Oncotherapy Science, Inc. Methods for diagnosing or treating prostate cancer
CN101440130B (zh) 2008-11-21 2011-07-27 中国人民解放军第四军医大学 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区
EP2995953B1 (en) 2009-03-24 2017-11-29 Biocept, Inc. Devices and methods of cell capture and analysis
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
CN102844443B (zh) 2009-09-21 2014-08-06 保罗·沃尔菲什 用于甲状腺癌诊断和治疗的方法和组合物
AR080155A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos anti-cd20 y su utilizacion
RS55738B1 (sr) 2010-02-24 2017-07-31 Immunogen Inc Imunokonjugati protiv folatnog receptora 1 i njihove upotrebe
ES2780192T3 (es) 2010-11-05 2020-08-24 Eisai Inc Folato receptor alfa como marcador diagnóstico y de pronóstico para cánceres que expresan folato receptor alfa
CN103717262B (zh) * 2011-03-29 2017-09-15 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
US20120259100A1 (en) * 2011-03-29 2012-10-11 Immunogen, Inc. Process for manufacturing conjugates of improved homogeneity
MY171008A (en) * 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
BR112013025415B1 (pt) 2011-04-01 2021-03-16 Immunogen, Inc uso de um imunoconjugado antirreceptor de folato 1 (folr1)
WO2012138749A1 (en) 2011-04-04 2012-10-11 Immunogen, Inc. Methods for decreasing ocular toxicity of antibody drug conjugates
US9156854B2 (en) 2011-04-18 2015-10-13 Immunogen, Inc. Maytansinoid derivatives with sulfoxide linker
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
MX362514B (es) 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
US20150306242A1 (en) 2012-10-04 2015-10-29 Immunogen, Inc. Process for preparing stable antibody maytansinoid conjugates
RU2015149285A (ru) 2013-05-14 2017-06-19 Иммьюноджен Инк. Схемы дозирования иммуноконъюгата anti-folr1
PL3038650T3 (pl) 2013-08-30 2021-11-22 Immunogen, Inc. Przeciwciała i testy do wykrywania receptora folianu 1
IL298044B2 (en) * 2013-10-08 2024-11-01 Immunogen Inc Dosing regimens of anti-FOLR1 immunoconjugate
US20150297744A1 (en) * 2014-03-28 2015-10-22 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
KR20200028510A (ko) 2014-07-01 2020-03-16 익스프레션 패톨로지, 인크. 화학요법 표적에 대한 srm 검정
CA2958882A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
KR102681168B1 (ko) 2017-02-28 2024-07-04 이뮤노젠 아이엔씨 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체
AU2018269173A1 (en) 2017-05-16 2019-11-28 Immunogen, Inc. Anti-FOLR1 immunoconjugates and anti-PD-1 antibody combinations

Also Published As

Publication number Publication date
CA2831426A1 (en) 2012-10-04
PT2694106T (pt) 2018-03-05
EA201791843A3 (ru) 2018-05-31
ZA202007440B (en) 2025-04-30
CN108743965A (zh) 2018-11-06
NZ615742A (en) 2015-09-25
PL2694106T3 (pl) 2018-06-29
IL281714A (en) 2021-05-31
IL262956B (en) 2020-04-30
WO2012135675A2 (en) 2012-10-04
KR101982317B1 (ko) 2019-05-27
SMT201800103T1 (it) 2018-05-02
LT2694106T (lt) 2018-04-25
US8709432B2 (en) 2014-04-29
UA125636C2 (uk) 2022-05-11
IL281714B2 (en) 2023-11-01
DK2694106T3 (en) 2018-03-05
US20220143208A1 (en) 2022-05-12
KR20140027969A (ko) 2014-03-07
CN103747802A (zh) 2014-04-23
IL228538B (en) 2018-12-31
KR102101160B1 (ko) 2020-04-16
CA2831426C (en) 2023-02-21
EP3636279A1 (en) 2020-04-15
JP6018621B2 (ja) 2016-11-02
CA3182262A1 (en) 2012-10-04
AU2017202927A1 (en) 2017-05-25
KR20240017965A (ko) 2024-02-08
MY180894A (en) 2020-12-11
CN114441757A (zh) 2022-05-06
EA201391351A1 (ru) 2014-11-28
ES2661466T3 (es) 2018-04-02
UA113403C2 (xx) 2017-01-25
EP3636279B1 (en) 2023-09-13
NO2893540T3 (cg-RX-API-DMAC7.html) 2018-06-09
BR112013025415A2 (pt) 2016-12-27
AU2019202611B2 (en) 2021-05-06
EP2694106B1 (en) 2017-12-13
RS56916B1 (sr) 2018-05-31
SG193514A1 (en) 2013-10-30
IL281714B1 (en) 2023-07-01
US20180200383A1 (en) 2018-07-19
JP2014513068A (ja) 2014-05-29
KR20230013283A (ko) 2023-01-26
EP4309671A2 (en) 2024-01-24
IL228538A0 (en) 2013-12-31
JP2016147901A (ja) 2016-08-18
MY186591A (en) 2021-07-29
EP2694106A2 (en) 2014-02-12
SG10201602553VA (en) 2016-05-30
HUE036172T2 (hu) 2018-06-28
EP3318273A1 (en) 2018-05-09
JP2021006547A (ja) 2021-01-21
CN103747802B (zh) 2018-06-01
MX2019010336A (es) 2019-10-14
TR201802659T4 (tr) 2018-03-21
AU2017202927B2 (en) 2019-01-17
IL303208A (en) 2023-07-01
ME03025B (me) 2018-10-20
AU2021206842A1 (en) 2021-08-12
AU2021206842B2 (en) 2024-12-19
KR20210088746A (ko) 2021-07-14
US20140363453A1 (en) 2014-12-11
JP2019194257A (ja) 2019-11-07
EA028805B1 (ru) 2018-01-31
AU2019202611A1 (en) 2019-05-02
IL273614A (en) 2020-05-31
JP2022062219A (ja) 2022-04-19
MX2013011098A (es) 2013-12-16
AU2012236219B2 (en) 2017-02-23
KR20200039843A (ko) 2020-04-16
MX340640B (es) 2016-07-19
HRP20180358T1 (hr) 2018-04-06
US20120282175A1 (en) 2012-11-08
NZ711375A (en) 2017-02-24
SI2694106T1 (en) 2018-04-30
KR102489185B1 (ko) 2023-01-17
EP4309671A3 (en) 2024-03-20
IL262956A (en) 2018-12-31
BR112013025415B1 (pt) 2021-03-16
JP2018118997A (ja) 2018-08-02
AU2012236219A1 (en) 2013-10-10
JP2024099612A (ja) 2024-07-25
ES2965109T3 (es) 2024-04-11
CY1119960T1 (el) 2018-12-12
HK1254759A1 (en) 2019-07-26
US11135305B2 (en) 2021-10-05
WO2012135675A3 (en) 2012-12-06
EP2694106A4 (en) 2015-04-08
EA201791843A2 (ru) 2017-12-29
EP3318273B1 (en) 2019-08-21
US20250228960A1 (en) 2025-07-17
KR20190058696A (ko) 2019-05-29

Similar Documents

Publication Publication Date Title
ZA202007440B (en) Methods for increasing efficacy of folr1 cancer therapy
AU2011328009A8 (en) Compounds and methods for treating pain
IN2015MN00001A (cg-RX-API-DMAC7.html)
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
PL3791896T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
WO2013149171A3 (en) Methods for increasing efficacy of cd37-based therapy
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
MY171561A (en) Conjugates for treating diseases caused by psma expressing cells
MY201478A (en) Antibodies and assays for detection of folate receptor 1
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
WO2015009726A3 (en) Medical uses of cd38 agonists
PH12015502112A1 (en) Cancer treatment using antibodies that bind cell surface grp78
IN2014MN01945A (cg-RX-API-DMAC7.html)
IN2014MN01944A (cg-RX-API-DMAC7.html)
MX2019014301A (es) Metodos de diagnostico para detectar y medios para contrarrestar trastornos mieloproliferativos o linfoproliferativos.
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
MX2021000258A (es) Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
AU2012900259A0 (en) Agents for use in cancer therapy
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists
HK1202239A1 (en) Combination drug therapy for the treatment of solid tumors
WO2014009245A3 (en) Novel drug target indentification methods
AU2012904722A0 (en) Agents for cancer therapy or prophylaxis and uses therefor